Evidence map›Paper›PMID 33190090›Full record

ArticleNeoplasia (New York, N.Y.)2021

Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes.

Beatriz Fernández-Blanco, Ana Pilar Berbegall, Susana Martin-Vañó, Victoria Castel, Samuel Navarro, Rosa Noguera

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Neuroblastoma Patients' Outcome and Chromosomal Instability.International journal of molecular sciences · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Beatriz Fernández-BlancoPathology Department, Medical School, University of Valencia-INCLIVA, Valencia, Spain.
Ana Pilar BerbegallPathology Department, Medical School, University of Valencia-INCLIVA, Valencia, Spain; CIBERONC, Madrid, Spain.
Susana Martin-VañóPathology Department, Medical School, University of Valencia-INCLIVA, Valencia, Spain; CIBERONC, Madrid, Spain.
Victoria CastelClinical and Translational Oncology Research Group, Investigation Institute La Fe, Valencia, Spain.
Samuel NavarroPathology Department, Medical School, University of Valencia-INCLIVA, Valencia, Spain; CIBERONC, Madrid, Spain.
Rosa NogueraPathology Department, Medical School, University of Valencia-INCLIVA, Valencia, Spain; CIBERONC, Madrid, Spain. Electronic address: rosa.noguera@uv.es.
Universitat de València · ESInstituto de Investigación Sanitaria La Fe · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival in high-risk neuroblastoma (HR-NB) patients remains poor despite multimodal treatment. We aimed to identify HR-NB patients with worse outcomes by analyzing the genomic instability derived from segmental chromosomal aberrations. We calculated 3 genomic instability indexes for primary tumor SNP array profiles from 127 HR-NB patients: (1) Copy number aberration burden (%gains

Indexed as

Genetic VariationGenomic InstabilityChromosome AberrationsDNA Copy Number VariationsFemaleGene AmplificationGenetic Association StudiesGenetic Predisposition to DiseaseHumansMaleNeuroblastomaPatient Outcome AssessmentPloidiesPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsCopy number aberration burdenCopy number loadGenomic imbalanceNet genomic loadSegmental chromosomal aberrations

Identifiers

PMID33190090
PMCPMC7674617
OpenAlexW3102192307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.